Primary human bone marrow hematopoietic progenitors are multipotent cells that can differentiate into several lineages (e.g., myeloid,erythroid and megakaryocytic cells). The myeloid, erythroid and megakaryocytic EasyDiff™ Supplements allow differentiation of CD34+ cells into three different hematopoietic lineages in 96-well plates.

  • Simply add appropriate volume of media (LGM-3™ or IMDM) to dilute supplement and mix with CD34+ cells in media
  • Plate into 96-well plate and differentiation into either erythroid, myeloid or megakryotic cells completed in 10-12 days


Discover our new website and eshop

Our new site is easier to use, mobile-friendly, and personalized.  


CD34+ day 0 (starting material)  Erythroid differentiation - day 10    Myeloid differentiation - day 10  Megakaryocytic differentiation – day 12
day 0 - CD34+
(starting material)
day 10 - Erythroid
day 10 - Myeloid
day 12 - Megakaryocytic


Features and Benefits

  • No need for methylcellulose or any substrate
  • No manual counting
  • Differentiation via quantification of the expression of lineage-specific markers


For more information and to purchase, visit our onlineshop.

These EasyDiff™ Supplements can be used for both drug discovery and toxicology.  Bone marrow progenitors are extremely sensitive to the toxic side effects of many drugs.  Early discovery and elimination of toxic compounds is an important component of the drug discovery process.  Studies have shown that the inhibitory activity of several drugs, as measured in in vitro assays of hematopoietic progenitor differentiation, correlate with their in vivo activities in various animal models (Volpe, 1996; Parchment, 1194).  Toxic effects of drugs can also be lineage-specific (Scheding, 1994; Silverstein, 1988).

  • Volpe DA, Tomaszewski JE, Parchment RE, Garg A, Flora KP, Murphy MJ and Grieshaber CK.  Cancer. Chemother. Pharmacol. 1996; 39:143-149.
  • Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ Jr. and Grieshaber CK.  J. Natl. Cancer Inst. 1994; 86:273-280.
  • Scheding S, Media JE, Nakeff A.  Exp. Hematol. 1994; 22:60-65.
  • Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP.  New Eng. J. Med. 1988; 318:1292-1294.